Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
Biomerica, Inc. (NASDAQ: BMRA) has successfully closed its underwritten public offering of 3,333,333 shares of common stock at a price of $2.40 per share, generating total gross proceeds of $8 million. The offering was led by Craig-Hallum Capital Group LLC as the sole managing underwriter. The net proceeds will be utilized for general corporate purposes, which include advancing clinical studies, enhancing sales and marketing efforts, research and development, acquisitions, and other operational needs. The shares were offered under a previously filed shelf registration statement with the SEC.
- Raised $8 million in gross proceeds from the stock offering.
- Proceeds will fund clinical studies, sales expansion, and product development.
- Potential dilution of existing shares from the stock offering.
IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value
Craig-Hallum Capital Group LLC acted as sole managing underwriter in connection with the offering.
Biomerica intends to use the net proceeds of the offering for general corporate purposes, including, without limitation, setting up and conducting clinical studies, expanding sales and marketing activities for existing and new products, research and development of new products, acquisitions, capital expenditures, and for other general working capital needs.
The shares of common stock described above were offered by Biomerica pursuant to a shelf registration statement on Form S-3 (File No. 333-239980) which was previously filed with the Securities and Exchange Commission (the “SEC”) on July 21, 2020, and amended by a pre-effective amendment filed with the SEC on September 11, 2020, and subsequently declared effective by the SEC on September 30, 2020. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on March 7, 2023, and are available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, by telephone at (612) 334-6300 or by email to prospectus@chlm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Biomerica
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Biomerica’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where Biomerica has multiple diagnostic and therapeutic products in development.
Corporate Contact
Allen Barbieri
949-645-2111
investors@biomerica.com
Forward-Looking Statements
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements, and include statements regarding the public offering. Biomerica’s actual results, and the timing of events, may differ materially from those indicated in or implied by these forward-looking statements due to numerous risks and uncertainties. Risks and uncertainties related to the public offering include uncertainties regarding market conditions and intended use of proceeds from the offering. Other risks and uncertainties include those identified under the heading “Risk Factors” in Biomerica’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q and in the final prospectus supplement and accompanying prospectus related to the offering filed with the SEC on March 7, 2023, and available on the SEC’s website at http://www.sec.gov, as well as other risks and uncertainties identified in documents that Biomerica files with the SEC from time to time. These statements are based on current expectations, estimates and projections based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Biomerica does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Source: Biomerica, Inc.
FAQ
What are the details of Biomerica's recent stock offering?
What will the funds from the Biomerica offering be used for?
Who managed the Biomerica public offering?
When was the Biomerica stock offering announced?
What potential risks are associated with Biomerica's stock offering?
